A pilot study of dose-dense paclitaxel with trastuzumab and lapatinib for node-negative HER2-overexpressed breast cancer Journal Article


Authors: Iyengar, N. M.; Fornier, M. N.; Sugarman, S. M.; Theodoulou, M.; Troso-Sandoval, T. A.; D'Andrea, G. M.; Drullinsky, P. R.; Gajria, D.; Goldfarb, S. B.; Comen, E. A.; Lake, D. E.; Modi, S.; Traina, T. A.; Lacouture, M. E.; Chen, M. F.; Patil, S.; Baselga, J.; Norton, L.; Hudis, C. A.; Dang, C. T.
Article Title: A pilot study of dose-dense paclitaxel with trastuzumab and lapatinib for node-negative HER2-overexpressed breast cancer
Abstract: Background Dual anti-HER2 therapy is effective for HER2-amplified breast cancer. Weekly paclitaxel, trastuzumab, and full-dose lapatinib (PTL) is not feasible because of grade 3 diarrhea. We conducted a phase II feasibility study of dose-dense (DD; every other week) PTL (ClinicalTrials.gov identifier, NCT01827163). Patients and Methods Eligible patients had HER2-positive breast cancer, tumor size ≤ 3 cm, and negative nodes. Treatment included paclitaxel (175 mg/m2 × 4, every 2 weeks with pegfilgrastim), trastuzumab (4 mg/kg load and then 2 mg/kg weekly), and lapatinib (1000 mg daily). After paclitaxel × 4, trastuzumab (6 mg/kg every 3 weeks) plus lapatinib were continued for 1 year. The primary endpoint was feasibility, defined as (1) > 80% of patients completing PTL without a dose delay or reduction, (2) grade 3 diarrhea rate < 20%, and (3) cardiac event rate < 4%. Results From May 2013 to November 2013, we enrolled 20 of 55 planned patients. The median age was 49 years (range, 34-74 years). One patient had immediate paclitaxel hypersensitivity and was deemed inevaluable. Only 13 of 19 evaluable patients (68%) completed PTL without a dose delay or reduction or unacceptable toxicities. Only 3 of 19 (16%) had grade 3 diarrhea. Rash was frequent, with all grades in 18 of 19 (95%) and grade 3 in 2 of 19 (11%). The study was stopped early because of excess toxicity. Conclusion The discontinuation rate during DD PTL was high, owing, in part, to an unexpectedly high incidence of rash. The trial was halted, because the initial discontinuation rate from overall toxicity made it unlikely that full accrual would demonstrate feasibility. © 2016 Elsevier Inc.
Keywords: drug toxicity; dose-dense chemotherapy; taxane; altto; dose schedule
Journal Title: Clinical Breast Cancer
Volume: 16
Issue: 2
ISSN: 1526-8209
Publisher: Elsevier Inc.  
Date Published: 2016-04-01
Start Page: 87
End Page: 94
Language: English
DOI: 10.1016/j.clbc.2015.09.009
PROVIDER: scopus
PUBMED: 26454612
PMCID: PMC4968930
DOI/URL:
Notes: Conference Paper -- Export Date: 4 April 2016 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Sujata Patil
    511 Patil
  2. Mario E Lacouture
    457 Lacouture
  3. Clifford Hudis
    905 Hudis
  4. Larry Norton
    760 Norton
  5. Chau Dang
    273 Dang
  6. Diana E Lake
    89 Lake
  7. Monica Nancy Fornier
    158 Fornier
  8. Devika Gajria
    31 Gajria
  9. Elizabeth Comen
    72 Comen
  10. Tiffany A Traina
    254 Traina
  11. Shanu Modi
    269 Modi
  12. Shari Goldfarb
    151 Goldfarb
  13. Neil Mukund Iyengar
    155 Iyengar
  14. Jose T Baselga
    484 Baselga
  15. Melanie Fanny Chen
    6 Chen